Cancer drug extension study offers continued hope for patients
NCT ID NCT00959647
First seen May 08, 2026 · Last updated May 22, 2026 · Updated 3 times
Summary
This study allowed people with certain cancers (ovarian, basal cell, or colorectal) who had already shown benefit from the drug vismodegib in earlier trials to keep receiving it. The main goal was to track safety and side effects over time. Only 19 patients took part, all of whom had previously been on vismodegib in a Genentech-sponsored study.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Hospital
Oakland, California, 94609, United States
-
Comprehensive Cancer Care
Palm Springs, California, 92262, United States
-
DermSurgery Associates, PA
Houston, Texas, 77030, United States
-
Irfan Firdaus, D.O.
Cincinnati, Ohio, 45242, United States
-
Johns Hopkins Univ Med Center
Baltimore, Maryland, 21231, United States
-
Karmanos Cancer Institute..
Detroit, Michigan, 48201, United States
-
Nevada Cancer Research Foundation
Las Vegas, Nevada, 89169, United States
-
Stanford Univ Medical Center
Stanford, California, 94305, United States
-
TGen Clinical Research Srvs
Scottsdale, Arizona, 85258, United States
-
University Of Michigan
Ann Arbor, Michigan, 48109-0934, United States
Conditions
Explore the condition pages connected to this study.